Related Experiment Video

Updated: Jul 10, 2026

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

CD47/SIRPα axis in cancer immunotherapy: Mechanisms, regulation, and therapeutic strategies

Yinghan Li1, Hongxu Yu1, Juanjuan Shi1

  • 1School of Biological Science and Technology, Jiangsu University, Zhenjiang, Jiangsu Province, the People's Republic of China.

European Journal of Pharmacology
|July 8, 2026
PubMed

Insights

Targeting the CD47/SIRPα "don't eat me" signal shows promise for cancer immunotherapy. This review explores strategies to balance antitumor effects with reduced hematotoxicity for safer treatment.

Area of Science:

  • Immunology
  • Oncology
  • Pharmacology

Background:

  • The CD47/SIRPα axis is a key "don't eat me" signal that promotes tumor immune evasion by blocking macrophage phagocytosis.
  • Therapeutic blockade of CD47/SIRPα offers potential for cancer immunotherapy but faces challenges in balancing efficacy with hematotoxicity, especially anemia.

Purpose of the Study:

  • To review recent advances in CD47 biology, including its regulation and signaling pathways.
  • To explore innovative therapeutic strategies for safely targeting the CD47 innate immune checkpoint.
  • To discuss emerging roles of CD47 beyond phagocytosis and next-generation therapeutic agents.

Main Methods:

  • Comprehensive literature review of CD47 biology and therapeutic strategies.
  • Synthesis of recent findings on CD47 regulation, crosstalk, and immune evasion.
  • Analysis of emerging evidence on CD47's role in the tumor microenvironment and T-cell function.

Main Results:

  • CD47's role extends beyond phagocytosis, influencing the tumor microenvironment and T-cell dysfunction.
  • Next-generation agents like tumor-selective bispecific antibodies and peptide inhibitors are being developed.
  • Combination regimens aim to enhance efficacy while minimizing systemic toxicity.

Conclusions:

  • Optimizing CD47-targeted therapies requires understanding its multifaceted roles and developing agents with improved safety profiles.
  • Next-generation strategies focus on maximizing therapeutic benefits and minimizing on-target toxicities like anemia.
  • Further research into CD47 biology and novel therapeutic approaches is crucial for advancing cancer immunotherapy.
Keywords:
CD47ImmunotherapyInnate immune checkpointPhagocytosisTumor immune evasion

More Related Videos

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...